06/09/2021 | Press release | Distributed by Public on 06/09/2021 06:06
Duesseldorf, June 9, 2021 - The virtual Annual General Meeting of Gerresheimer AG has approved the payment of a dividend of EUR 1.25 per share. 'All of our plants around the world managed the Covid situation well last year, maintained their production operations, and continued to supply our customers with products that are so important to the healthcare industry,' Dietmar Siemssen, Chief Executive Officer of Gerresheimer AG, told the Annual General Meeting. 'We were proactive in establishing additional capacities for injection vials early on in the Covid vaccination drive. In spite of the pandemic, we opened up new opportunities for growth and laid the foundations for our accelerated growth course. We are transforming our Gerresheimer into a growth company as innovation leader and solutions provider. That transformation is well underway.'
The dividend has been increased by 4% to EUR 1.25 per dividend-entitled share. In the prior year, the company paid a dividend of EUR 1.20 per share. The dividend is to be paid out on June 14, 2021.
The actions of the Management Board and Supervisory Board for the financial year 2020 were approved by a large majority. Deloitte GmbH Wirtschaftsprüfungsgesellschaft, Duesseldorf, was elected as auditor for the financial year 2021. The Annual General Meeting confirmed the remuneration system for the Management Board members and the remuneration of the Supervisory Board members. In addition, the Annual General Meeting adopted two resolutions on creating new authorized capital.
A total of 79.11% of the capital stock was represented at today's Annual General Meeting. The detailed voting results for all items on the Annual General Meeting's agenda are available at:
The speech by the Chief Executive Officer and the presentation on the Annual General Meeting are available at:
The Annual Report is available at:
Gerresheimer is the global partner for pharma, biotech, healthcare and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging and drug delivery devices. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence, focus on quality and customers. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 10,000 employees and generates annual sales of more than €1.4 billion. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.